Key result
Continuing antithrombotics during dental procedures safely avoids thromboembolic risks, as local bleeding remains manageable.
Why the study?
The management of dental patients on antiplatelets and anticoagulants is challenging due to balancing bleeding risk and thromboembolic complications when discontinuing these drugs.
Cross-Sectional
Answers are grounded in this paper and cite their sources.
Continuing antithrombotics in dental patients may lower thromboembolic risk; leaves open bleeding safety in Level 5 evidence.
An increasing number of dental patients are taking ‘blood thinner’ medications for various medical conditions. These drugs interfere with the body's normal clotting (stopping blood flow) mechanism. The standard of care has been to stop the aspirin and warfarin prior to dental procedures involving bleeding since these drugs are known to affect clot formation and coagulation. However, the patient is at a greater risk of developing thromboembolic complications and reinfarcts if these drugs were discontinue than occurence of excessive bleeding if they were continued. Bleeding can be effectively managed by local hemostatic measures. How to cite this article Daruwalla SF, Sidana S. Current Evidence-based Management of Patients on Antiplatelets and Anticoagulants in Dental Practice: A Questionnaire-based Survey of Interns and Staff. J Contemp Dent 2014;4(1):22-26.
No takes yet. Share an insight, caveat, or question.
Sidana et al. (2014) conducted a cross-sectional in Dental patients on antiplatelets and anticoagulants. Antiplatelets and anticoagulants vs. Discontinuation of therapy was evaluated. Continuing antiplatelets and anticoagulants during dental procedures is recommended as bleeding can be managed locally, avoiding greater thromboembolic risks from discontinuation.
Synapse has enriched 10 related papers. Consider them for comparative context: